Strategic partnerships Opportunity to pursue collaboration on IV nivolumab biosimilars via ongoing or expanding co-development and supply agreements with Shilpa Biologicals and Shilpa Medicare for the European market, leveraging Orion’s oncology focus and manufacturing capabilities.

Oncology pipeline Leverage Orion’s Phase 1/2 TEADES trial data for ODM-212 to engage potential pharma partners, CROs, and contract manufacturers for co-development, licensing, or strategic investments in TEAD inhibitor programs.

Manufacturing leverage Explore contract manufacturing, technology transfer, or toll manufacturing opportunities at Orion’s expanded Turku facilities and carbon-free production capabilities to support external partners seeking sustainable, scalable production.

Veterinary and AMO growth Position Orion’s expertise in human and veterinary pharmaceuticals and active pharmaceutical ingredients to potential customers seeking integrated supply, with cross-selling of generic and proprietary medicines across regional markets.

Sustainability selling point Highlight carbon-free production milestone and Nordic manufacturing footprint to attract customers and partners prioritizing ESG-aligned supply chains, potentially unlocking preferential terms and green financing opportunities.